These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34090364)

  • 1. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    Dhaka B; Sabarinathan R
    BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
    Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
    Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Barta JA; Pauley K; Kossenkov AV; McMahon SB
    Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
    Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
    Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
    Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
    Yan W; Liu G; Scoumanne A; Chen X
    Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide estrogen receptor β chromatin binding in human colon cancer cells reveals its tumor suppressor activity.
    Indukuri R; Jafferali MH; Song D; Damdimopoulos A; Hases L; Zhao C; Archer A; Williams C
    Int J Cancer; 2021 Aug; 149(3):692-706. PubMed ID: 33754337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
    Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.
    Lü Y; Cho T; Mukherjee S; Suarez CF; Gonzalez-Foutel NS; Malik A; Martinez S; Dervovic D; Oh RH; Langille E; Al-Zahrani KN; Hoeg L; Lin ZY; Tsai R; Mbamalu G; Rotter V; Ashton-Prolla P; Moffat J; Chemes LB; Gingras AC; Oren M; Durocher D; Schramek D
    Mol Syst Biol; 2024 Jun; 20(6):719-740. PubMed ID: 38580884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells.
    Wang X; Yan J; Shen B; Wei G
    Front Cell Dev Biol; 2021; 9():708066. PubMed ID: 34395436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer.
    Lu L; Huang W; Hu W; Jiang L; Li Y; Wu X; Yuan D; Li M
    Biochem Biophys Res Commun; 2019 Apr; 511(4):772-779. PubMed ID: 30833076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
    Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
    Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
    Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer.
    Kelkar MG; Thakur B; Derle A; Chatterjee S; Ray P; De A
    Breast Cancer Res Treat; 2017 Aug; 164(3):603-615. PubMed ID: 28528452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.